OBJECTIVES: Two billion people worldwide have been infected with hepatitis B virus and approximately 400 million present chronic disease. Part of chronically infected patients with HBV develop cirrhosis and liver failure. Two strategies are adopted for treatment of chronic hepatitis B: a) use of interferon (conventional and pegylated) for a limited timeframe and b) use of nucleoside/tide analogs for a determined period. This analysis aims to assess the Incremental cost-utility ratio for peginterferonalfa-2a (40 KD) versus lamivudine, for treatment of HBeAgpositive and HBeAg-negative patients with hepatitis B, from the perspective of the National Health Service. METHODS: A Markov model was used to estimate the clinical and economic impact of the incorporation of peginterferon-alfa-2a (40 KD). Clinical stages were based on liver histology, cirrhotic decompensation, liver cancer and liver transplantation. Costs were estimated based on resource utilization described in a Delphi panel with experts. Response and seroconversion rates with peginterferon alfa-2a (40 KD) were 36% for HBeAg-negative, and 32% for HBeAg-positive patients. For lamivudine, rates were 23% and 19%, respectively. Data concerning the quality-of-life were extracted from the international literature, due to the lack of local data. A lifetime horizon was assumed. RESULTS: The ICER (peginterferon-alfa-2a vs. lamivudine) was R$ 20,192 HBeAgnegative patients, and R$ 33,749 for HBeAg-positive patients, assuming a discount rate of 3%. A probabilistic sensitivity analysis was conducted using second-order Monte Carlo simulation. Tested parameters were costs per stage, treatment costs, discount rate, and responsiveness to treatment. The 95% confidence interval for the ICER ranged from R$ 12,275 to R$ 35,048 for HBeAg-negative patients, and R$ 17,771 to R$ 67,430 for HBeAg-positive patients. CONCLUSION: The study suggests that therapy with peginterferon-alfa-2a (40 KD) has a robust and favorable cost-utility ratio in the Brazilian public health system for both serological profiles. (APRICOT Torriani et al. 2004) has demonstrated the efficacy of alphapeginterferon-2a (40KD) + ribavirin (PEG + RBV) treatment and its superiority to alphainterferon2a + ribavirin (IFN + RBV) for the treatment of chronic hepatitis C in HIV-infected patients. However, incremental costeffectiveness ratios have not been established yet for this group of patients for the private payer perspective in Brazil. METHODS: A cost-utility analysis was conducted attempting to estimate costs and outcomes in long term timeframe for PEG + RBV, IFN + RBV and no specific treatment for co-infected patients. To project the disease path, a markov model based on published literature was constructed. Clinical practice and medical resource utilization was assessed by a Delphi panel with Brazilian experts. Both costs and outcomes were discounted at a 3% annual rate. Payer perspective was adopted regarding direct costs for a lifetime perspective. The model was submitted to a univariate and a probabilistic sensitivity analysis, beyond Monte Carlo secondorder simulation, to evaluate uncertainties on ICER estimates. RESULTS: The ICER for the treatment with PEG + RBV compared with IFN + RBV was R$36,645 per QALY with a 95% confidence interval between R$22,504 to R$64,175. The ICER for the treatment with PEG + RBV compared with no specific treatment was R$28,912 per QALY and the 95% confidence interval between R$18,768 to R$50,572. CONCLUSION: The study results suggest that the treatment with alfapeginterferon-2a (40 KD) can be considered a cost-effective alternative, as it improves quality and quantity of life regarding other options and it offers an incremental cost-effectiveness ratio robust and acceptable for the private payer in Brazil.
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PIN38 AFFORDABILITY OF ANTIMALARIAL DRUGS IN BENIN CITY, NIGERIA
Udezi WA 1 , Usifoh CO 1 , Eze UI 2 1 University of Benin, Benin, Edo, Nigeria, 2 Olabisi Onabanjo University, Shagamu, Ogun, Nigeria OBJECTIVES: The purpose of this study was to evaluate the affordability of Antimalarial Drugs using real world data from private pharmacies, missionary and government hospitals in Benin city, Nigeria. METHODS: The mean Ϯ SD of prices that patients prescribed Antimalarials in Benin city pay for a standard regimen when they have malaria was collected from private pharmacies, missionary and government hospitals. Minimum wage was obtained directly from the least paid unskilled government workers.The data was used to develop a stochastic monte carlo model that calculates affordability of an Antimalarial drug (in days' wages). Two markov models that use 2007 data to project prices of antimalarial drugs and monthly minimum wages into the future using inflation rates, prices of antimalarials, percentage increase in wages and a fixed discount rate of 5% were also built. Results of the markov models serve as inputs for the monte carlo simulations so that affordability can thus be projected into the future for the next 10 years. All three models reported 1000 observations averaged over 10 repeated simulations. RESULTS: Branded Antimalarial drugs were less affordable compared to the lowest priced generic versions (p < 0.0001). Branded chloroquine tablets were 290% more expensive than the unbranded and the least paid unskilled government worker would need to spend about 20 days' wages to treat malaria with artemether 80 mg/ml injection. Antimalarials from missionary and government hospitals were not necessarily more affordable than those bought in private pharmacies.Peadiatric dihydroartemisinin 160 mg/80 ml may become 182% less affordable in 2012 and 226% less affordable by 2017 (p < 0.0001). All Antimalarials studied exhibited a similar trend. Sensitivity analyses showed that these findings were robust. CONCLUSION: Unless deliberAbstracts A447
